Loading…
SciSparc Ltd. is projected to decline to $3.75 by 2027, a -15% move from its current price of $4.39. SPRC is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $4.10 | $4.39 | $4.69 | -0.09% |
| May 30 | $3.99 | $4.38 | $4.82 | -0.18% |
| May 31 | $3.90 | $4.38 | $4.91 | -0.28% |
| Jun 1 | $3.83 | $4.37 | $5.00 | -0.37% |
| Jun 2 | $3.76 | $4.37 | $5.07 | -0.46% |
| Jun 3 | $3.71 | $4.37 | $5.14 | -0.55% |
| Jun 4 | $3.65 | $4.36 | $5.21 | -0.64% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $3.65 | $4.36 | $5.21 | -0.64% |
| Week 2 | $3.37 | $4.33 | $5.56 | -1.29% |
| Week 3 | $3.17 | $4.31 | $5.85 | -1.92% |
| Week 4 | $3.00 | $4.28 | $6.09 | -2.55% |
| Week 5 | $2.86 | $4.25 | $6.31 | -3.18% |
| Week 6 | $2.74 | $4.22 | $6.51 | -3.81% |
| Week 7 | $2.63 | $4.20 | $6.70 | -4.43% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
SciSparc Ltd. is a clinical-stage pharmaceutical company focused on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution.
The company sells hemp seed oil-based products and has development and manufacturing agreements with Procaps to develop and commercially manufacture SCI-110, palmitoylethanolamide oral tablets and CannAmide in softgel capsule form. It also has an agreement with The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation; and a collaboration with Clearmind Medicine Inc. The company was formerly known as Therapix Biosciences Ltd.
and changed its name to SciSparc Ltd. in January 2021. SciSparc was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel.
SciSparc Ltd. (SPRC) is a healthcare company trading at $4.27 per share, with a market cap of $2.45M and a rank of 5460. These fundamentals place it among smaller-cap healthcare names with a cannabinoid-therapy focus.
The 30-day technical picture shows bearish sentiment, with RSI14 at 40, and moving averages at SMA50 $5.03 and SMA200 $17.69. The stock has near-term support at $3.07 and resistance at $9.03. The 30-day range runs from $2.69 to $6.77, and annualized volatility is listed at 100%.
Looking ahead, the year-by-year forecast provides a path with fluctuating averages and ROIs. The 2026 average price is $4.27 with 0% ROI (Neutral). The 2030 average is $3.71 with -13.2% ROI (Neutral). The forecast diverges into positive territory in 2031-2033, then turns bullish in 2040 (average $5.30, ROI 24.1%) and 2050 (average $12.77, ROI 199%).
A major floor 30.3% below — a decisive break under it would weaken the trend.
The nearest floor, 22.8% below — buyers have tended to step in here.
The nearest ceiling, 105.7% above — a clean break opens room to run.
A major ceiling 156.1% above — clearing it would confirm fresh momentum.
Key SPRC support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of SPRC market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $4.29 | Buy | $4.41 | Sell |
| MA 10 | $4.52 | Sell | $4.70 | Sell |
| MA 20 | $5.79 | Sell | $5.12 | Sell |
| MA 50 | $5.03 | Sell | $5.61 | Sell |
| MA 100 | $6.15 | Sell | $8.74 | Sell |
| MA 200 | $17.26 | Sell | $25.57 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 40.09 | Neutral |
| Stoch RSI (14) | 20.89 | Neutral |
| CCI (20) | -71.35 | Neutral |
| Williams %R (14) | -88.93 | Info |
| MACD (12,26,9) | -0.22 | Sell |
| ROC (12) | -29.76 | Sell |
| Bollinger %B (20,2) | 0.27 | Neutral |
| Stochastic %K (14) | 11.07 | Buy |
| TRIX (15) | -0.29 | Sell |
| Awesome (5,34) | -1.22 | Sell |
| Ultimate (7,14,28) | 34.43 | Neutral |
| Momentum (10) | -1.04 | Sell |
| Aroon Osc (25) | -60.00 | Sell |
| Hull MA (9) | 4.27 | Buy |
| ADX (14) | 24.02 | Sell |
| ATR (14) | 0.33 | Info |
The 30-day picture shows a bearish tilt with the stock trading below key moving averages. RSI is 40, indicating subdued momentum. The SMA50 stands at $5.03 and the SMA200 at $17.69, reinforcing the near-term bearish stance.
Support is noted at $3.07 and resistance at $9.03. The 30-day range spans from $2.69 to $6.77, illustrating a relatively wide trading window in the near term.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $3.06 | $4.39 | $6.25 | 0% | Neutral | |
| $2.70 | $3.75 | $5.64 | -15% | Neutral | |
| $2.48 | $3.66 | $5.86 | -17% | Bearish | |
| $2.17 | $3.37 | $5.65 | -23% | Bearish | |
| $2.37 | $3.85 | $6.71 | -12% | Neutral | |
| $2.88 | $4.90 | $8.84 | +12% | Neutral | |
| $2.85 | $5.06 | $9.40 | +15% | Neutral | |
| $2.78 | $5.12 | $9.79 | +17% | Neutral | |
| $2.31 | $4.44 | $8.70 | +1% | Neutral | |
| $2.05 | $4.10 | $8.21 | -7% | Neutral | |
| $2.42 | $5.37 | $11.81 | +22% | Bullish | |
| $5.94 | $13.21 | $30.38 | +201% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $3.06 | $4.39 | $5.18 | +0.00% |
| June 2026 | $3.38 | $4.06 | $5.04 | -7.54% |
| July 2026 | $3.31 | $4.04 | $5.14 | -0.58% |
| August 2026 | $3.50 | $4.32 | $5.62 | +7.14% |
| September 2026 | $3.46 | $4.33 | $5.71 | +0.15% |
| October 2026 | $3.33 | $4.21 | $5.63 | -2.84% |
| November 2026 | $3.46 | $4.41 | $5.97 | +4.77% |
| December 2026 | $3.55 | $4.56 | $6.25 | +3.57% |
Click any year to see its month-by-month SPRC forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect SPRC to range from $3.06 to $6.25 through 2026. The $4.39 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The SPRC price prediction for 2027 points to an average of $3.75 (low $2.70, high $5.64) — a potential decline of -15% on today's $4.39. Price action looks broadly range-bound.
In 2028, SPRC is projected to trade between $2.48 and $5.86, averaging $3.66 — a potential decline of -17% from today's $4.39. That is -2% versus the projected 2027 average. Expect choppier, lower action through this leg of the cycle.
SciSparc Ltd.'s 2029 outlook centres on $3.37, within a $2.17 to $5.65 range. That is -8% versus the projected 2028 average. That marks a -23% change versus current levels. A cyclical pullback looks likely — prices rarely move in a straight line.
By 2030, SPRC could reach as high as $6.71, with a base case around $3.85 and support toward $2.37 — roughly -12% from $4.39. A consolidation phase looks the most probable path here.
Expect SPRC to range from $2.88 to $8.84 through 2031. The $4.90 average target implies a +12% move from current prices. That is up +27% on the projected 2030 average. Price action looks broadly range-bound.
The SPRC price prediction for 2032 points to an average of $5.06 (low $2.85, high $9.40) — a potential gain of +15% on today's $4.39. A consolidation phase looks the most probable path here.
In 2033, SPRC is projected to trade between $2.78 and $9.79, averaging $5.12 — a potential gain of +17% from today's $4.39. That is up +1% on the projected 2032 average. Price action looks broadly range-bound.
SciSparc Ltd.'s 2034 outlook centres on $4.44, within a $2.31 to $8.70 range. That is -13% versus the projected 2033 average. That marks a +1% change versus current levels. A consolidation phase looks the most probable path here.
By 2035, SPRC could reach as high as $8.21, with a base case around $4.10 and support toward $2.05 — roughly -7% from $4.39. Price action looks broadly range-bound.
Expect SPRC to range from $2.42 to $11.81 through 2040. The $5.37 average target implies a +22% move from current prices. That is up +31% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The SPRC price prediction for 2050 points to an average of $13.21 (low $5.94, high $30.38) — a potential gain of +201% on today's $4.39. Momentum favours further upside here.
Investing $1,000 in SPRC today (≈ 227.790433 SPRC) could be worth
$3,009.1
+$2,009.1 (+201%) by 2050 · US Dollar
Based on the average projected SPRC price of $13.21 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in SPRCwould be worth at today's price.
$1,000 invested in SPRC on May 27, 2025 (≈ 17.290867 SPRC) would be worth
$75.91
-$924.09 (-92.4%) today · 0.08× · US Dollar
Based on a SPRC entry price of $57.83 vs. today's $4.39.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $4.1 | $1,070.73 | +7.1% |
| 1 month ago | $8.73 | $502.86 | -49.7% |
| 3 months ago | $5.27 | $832.39 | -16.8% |
| 6 months ago | $19.8 | $221.72 | -77.8% |
| 1 year ago | $57.83 | $75.91 | -92.4% |
| All time (4.7y) ago | $22,113 | $0.2 | -100.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our SPRC forecast.
Our base-case forecast reaches $8.80 around 2050.
Implied market cap at $8.80: $5.04M
The multi-year forecast depicts a volatile path with episodes of downside before eventual upside. The 2026 average price is $4.27 with 0% ROI and Neutral sentiment. The pattern shows negative ROIs in 2027 (-15.9%), 2028 (-15.3%), and 2029 (-23.3%), then neutral again in 2030 with an average of $3.71 and ROI -13.2%.
From 2031 to 2033, the outlook turns more favorable, with ROIs of 13.1% (2031), 14.8% (2032), and 16.1% (2033), and average prices around $4.83–$4.96. The 2034 forecast shows a small positive ROI of 2.3% with an average near $4.37, and 2035 carries a negative ROI of -7.9% with an average of $3.93.
The landscape shifts markedly by 2040, where the average price rises to $5.30 and ROI reaches 24.1% (bullish). By 2050, the forecast envisions a substantial jump to an average of $12.77 and ROI of 199% (bullish), underscoring a large potential upside alongside persistent uncertainty and volatility.
Tap a question to reveal the answer.
The forecasted average price for 2030 is $3.71, with a range from $2.28 to $6.47; ROI -13.2% and sentiment Neutral.
Forecasts show a mix of outcomes: 2026 average $4.27 with 0% ROI (Neutral), followed by negative ROIs in 2027 (-15.9%), 2028 (-15.3%), and 2029 (-23.3%), then positive ROIs beginning 2031 (13.1%), 2032 (14.8%), and 2033 (16.1%). The later years 2040 (24.1%) and 2050 (199%) show bullish potential, but volatility and risk remain.
No. The 2035 forecast max is $7.88 and avg $3.93; ROI -7.9%.
Current price is $4.27 per share and market cap is $2.45M.
SciSparc's programs include SCI-110, SCI-210, and CannAmide; it sells hemp seed oil-based products and has a Procaps agreement for development/manufacture, plus collaborations with The Israeli Medical Center for Alzheimer's and Clearmind Medicine Inc.; it was formerly Therapix Biosciences Ltd. and was incorporated in 2004, headquartered in Tel Aviv-Yafo, Israel.
SciSparc Ltd. Community Discussion
0Share your SciSparc Ltd. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.